


Product Name : PF-07321332
Cat. No. : PC-72607
CAS No. : 2628280-40-8
Molecular Formula : C₂₃H₃₂F₃N₅O₄
Molecular Weight : 499.535
Target : SARS-CoV-2 Inhibitors
Solubility : 10 mM in DMSO



Biological Activity

PF-07321332 (Nirmatrelvir, Paxlovid) is the first, orally bioavailable **SARS-CoV-2 main protease (Mpro)** inhibitor with biochemical Ki of 3.11 nM.

PF-07321332 demonstrated highly potent Vero E6 antiviral activity (EC₅₀=74.5 nM).

PF-07321332 inhibited SARS-CoV-2-induced CPE in Vero E6 cells enriched for ACE2 with EC₅₀ of 4.48 uM.

PF-07321332 demonstrated potent inhibition in FRET Mpro assays representing Mpro from all coronavirus types known to infect humans, including beta-coronaviruses (SARS-CoV-2, SARS-CoV-1, HKU1, OC43, and MERS-CoV) as well as alpha-coronaviruses (229E and NL63).

PF-07321332 inhibited SARS-CoV-2 replication as assessed using a nanoluciferase reporter virus in A549-ACE2 cells with EC₅₀ and EC₉₀ values of 77.9 and 215 nM, respectively, with no cytotoxicity.

PF-07321332 demonstrated potent antiviral activity against SARS-CoV-1 (EC₉₀=317 nM), MERS-CoV (EC₉₀=351 nM), and 229E (EC₉₀=620 nM) in CPE assays.

PF-07321332 demonstrated in vivo efficacy against SARS-CoV-2 MA10 infection in mouse-adapted SARS-CoV-2 model.

PF-07321332 demonstrated a favorable off-target selectivity profile in a broad panel of G protein-coupled receptors, kinases, transporters, and phosphodiesterase enzyme inhibitor screens, and was devoid of activity against the cardiac ion channels Kv1.1, Cav1.2, and Nav1.5, and was not mutagenic or clastogenic in in vitro genetic toxicity studies.

References

Pavan M, et al. *J Enzyme Inhib Med Chem*. 2021 Dec;36(1):1646-1650.

Owen DR, et al. *Science*. 2021 Dec 24;374(6575):1586-1593.

Alugubelli YR, et al. *bioRxiv*. 2021 Dec 21:2021.12.18.473330.

Abe K, et al. *Sci Rep*. 2022 Jan 25;12(1):1299.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com